Can Tenofovir Plus Lamivudine Plus Dolutegravir Be Taken During Pregnancy?
Yes, the combination of tenofovir (TDF or TAF), lamivudine (3TC), and dolutegravir (DTG) is safe and highly effective during pregnancy and is now a preferred first-line regimen for pregnant women living with HIV.
Current Guideline Recommendations
The most recent 2025 International Antiviral Society-USA guidelines explicitly recommend TAF/XTC plus dolutegravir (evidence rating: AIa) as the preferred regimen during pregnancy, with TDF/XTC plus dolutegravir as a suitable alternative if tenofovir alafenamide is not available (evidence rating: AIa) 1. This represents a significant evolution from older 2017 guidelines that favored zidovudine-based regimens 2.
Key Evidence Supporting Use in Pregnancy
Superior Efficacy
The landmark IMPAACT 2010/VESTED trial (2021) demonstrated that dolutegravir-containing regimens achieved 98% viral suppression at delivery compared to 91% with efavirenz-based regimens (p=0.0052) 3. This superior virologic control is critical for preventing mother-to-child transmission.
Safety Profile
The combination of dolutegravir, emtricitabine, and tenofovir alafenamide had the lowest frequency of composite adverse pregnancy outcomes (24%) compared to other regimens (33%) 3. Specifically:
- Lower preterm delivery rates (6% vs 12% with efavirenz regimen, p=0.023)
- Significantly lower neonatal mortality (1% vs 5% with efavirenz, p=0.019)
- No new safety signals identified 3
Neural Tube Defect Concerns Resolved
Updated surveillance data from Tsepamo and Eswatini studies (>14,000 DTG exposures from conception) indicate no increased risk of neural tube defects with dolutegravir 4. The FDA label notes that while an observational study showed an association with neural tube defects, alternative treatment should be considered primarily at the time of conception through the first trimester 5. However, dolutegravir may be used during the second and third trimesters if the expected benefit justifies the potential risk 5.
Adequate Drug Exposure
Pharmacokinetic studies confirm that dolutegravir exposure in the third trimester is adequate, with 93% of individual trough concentrations exceeding therapeutic thresholds 6. The geometric mean ratio for AUC in third trimester versus postpartum was 0.86 (90% CI 0.68-1.10), indicating no clinically significant reduction 6.
Practical Implementation
When to Use This Regimen
- Preferred for most pregnant women starting or continuing ART during pregnancy
- Can be initiated at any gestational age, though consider alternatives in the first trimester if conception timing is uncertain 5
- Particularly appropriate for women already virologically suppressed on this regimen who become pregnant
Formulation Considerations
- Tenofovir alafenamide (TAF) is preferred over tenofovir disoproxil fumarate (TDF) due to better pregnancy outcomes 3
- Single-tablet fixed-dose combinations improve adherence
- Standard dosing: dolutegravir 50 mg once daily plus tenofovir/lamivudine once daily
Monitoring Requirements
- Pregnancy testing before initiation in those of childbearing potential 5
- Regular viral load monitoring (standard HIV care)
- Counsel regarding consistent contraception if not actively trying to conceive 5
Important Caveats
First Trimester Considerations
While the neural tube defect signal has been largely refuted, initiation of dolutegravir is not recommended in those actively trying to become pregnant unless there is no suitable alternative 5. For women who become pregnant on dolutegravir in the first trimester, assess risks and benefits of continuing versus switching, though continuation is generally reasonable given updated safety data 5.
When NOT to Use
- Do NOT use the 2-drug regimen DTG/3TC during pregnancy as initial therapy—it is not recommended due to inadequate data 1. The 3-drug regimen with tenofovir is required.
- Avoid if documented integrase inhibitor resistance is present
- Consider alternatives if severe hepatotoxicity or hypersensitivity reactions occur 5
Hepatitis B Co-infection
This regimen is particularly advantageous in HBV co-infection as both tenofovir and lamivudine have anti-HBV activity 7. The older 2017 guidelines noted concerns about lamivudine resistance in HBV, but tenofovir provides robust HBV coverage 2.
Comparison to Older Recommendations
The 2017 BMJ guidelines recommended zidovudine/lamivudine-based regimens over tenofovir/emtricitabine, with a strong recommendation against tenofovir/emtricitabine/lopinavir-ritonavir due to increased early neonatal death and preterm delivery 2. However, these concerns were specific to the lopinavir-ritonavir combination and do not apply to dolutegravir-based regimens, which have demonstrated superior safety 3.
The evidence strongly supports tenofovir/lamivudine/dolutegravir as a safe, effective, and preferred option for pregnant women living with HIV, with the caveat of considering alternatives during periconception and first trimester if feasible.